Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
N-Glycolyl Muramyl Dipeptide elicits Cellular Immunity of Complete Freund's Adjuvant
FY 2015-16
Summary
The immune system uses antibodies and cells to protect the body. Most vaccines used today induce antibodies to block extracellular infectious agents. However, vaccines that produce cell-mediated immunity (CMI) are still critically needed to prevent intracellular infections by bacteria, viruses and parasites. Experimental models of CMI have classically used a specific reagent called Complete Freund's Adjuvant, which is composed of mineral oil and the cell walls of bacteria called mycobacteria. A driving goal of the proposed research is to understand why Freund, and other immunologists, have relied so heavily on mycobacteria for their studies of CMI. Specifically, it is known that a certain component of the bacterial cell wall is critical for the induction of CMI; this part is called muramyl dipeptide. In mycobacteria, this molecule is produced in an unusual, modified form. In my studies, I will use two sets of reagents: 1) conventional and modified muramyl dipeptide, and 2) mycobacteria that have been engineered to produce either form of muramyl dipeptide. Using these tools, I aim to monitor the degree of antibody versus cellular immunity in experimental models of infection and immunization. The data are expected to explain how the mycobacterial version of muramyl dipeptide contributes to deviation from antibody-based to cellular immunity. Understanding the processes that mediate these responses will aid in the development of vaccines that elicit a CMI response. For instance, we currently lack an effective vaccine to prevent tuberculosis, a disease caused by mycobacteria. The same CMI processes uncovered in the studies proposed are also expected to inform the design of vaccines for other diseases caused by intracellular pathogens.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350056
Name
Dube Jean-Yves
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
N-Glycolyl Muramyl Dipeptide elicits Cellular Immunity of Complete Freund's Adjuvant
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adjuvancy; Cell-Mediated Immunity (Cmi); Freund'S Adjuvant; Muramyl Dipeptide; Mycobacteria; Mycobacterium Tuberculosis; N-Glycolyl Muramyl Dipeptide; Nucleotide-Binding Oligomerization Domain Containing (Nod) 2; Peptidoglycan; Vaccination
Abstract
The immune system uses antibodies and cells to protect the body. Most vaccines used today induce antibodies to block extracellular infectious agents. However, vaccines that produce cell-mediated immunity (CMI) are still critically needed to prevent intracellular infections by bacteria, viruses and parasites. Experimental models of CMI have classically used a specific reagent called Complete Freund's Adjuvant, which is composed of mineral oil and the cell walls of bacteria called mycobacteria. A driving goal of the proposed research is to understand why Freund, and other immunologists, have relied so heavily on mycobacteria for their studies of CMI. Specifically, it is known that a certain component of the bacterial cell wall is critical for the induction of CMI; this part is called muramyl dipeptide. In mycobacteria, this molecule is produced in an unusual, modified form. In my studies, I will use two sets of reagents: 1) conventional and modified muramyl dipeptide, and 2) mycobacteria that have been engineered to produce either form of muramyl dipeptide. Using these tools, I aim to monitor the degree of antibody versus cellular immunity in experimental models of infection and immunization. The data are expected to explain how the mycobacterial version of muramyl dipeptide contributes to deviation from antibody-based to cellular immunity. Understanding the processes that mediate these responses will aid in the development of vaccines that elicit a CMI response. For instance, we currently lack an effective vaccine to prevent tuberculosis, a disease caused by mycobacteria. The same CMI processes uncovered in the studies proposed are also expected to inform the design of vaccines for other diseases caused by intracellular pathogens.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dube, Jean-Yves
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~